Colorimetric in vitro susceptibility testing of penicillins, cephalosporins, macrolides, streptogramins, tetracyclines, and aminoglycosides against Borrelia burgdorferi isolates

被引:32
作者
Hunfeld, KP [1 ]
Kraiczy, P [1 ]
Wichelhaus, TA [1 ]
Schäfer, V [1 ]
Brade, V [1 ]
机构
[1] Univ Hosp Frankfurt, Inst Med Microbiol, D-60596 Frankfurt, Germany
关键词
spirochaetes; Borrelia burgdorferi; antimicrobial; susceptibility;
D O I
10.1016/S0924-8579(00)00116-3
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The spectrum of antibiotic susceptibility of Borrelia burgdorferi has been only partially defined. In the present study the effectiveness of 12 antimicrobials, belonging to six different antibiotic classes have been tested against Borrelia burgdorferi s.s. (N = 3), Borrelia garinii (N = 3), Borrelia afzelii (N = 3), Borrelia valaisiana (N = 1), and Borrelia bissettii (N = 1) isolates. These isolates were analysed by a new standardised colorimetric minimal inhibitory concentration (MIC) method based upon colour changes that result from actively metabolizing spirochaetes after 72 h of incubation. Piperacillin (MIC90: 0.08 mg/l), ceftriaxone (MIC90: 0.04 mg/l), cefotaxime (MIC90: 0.15 mg/l), azithromycin (MIC90: 0.015 mg/l), roxithromycin (MIC90: 0.05 mg/l) and quinupristin/dalfopristin (MIC90: 0.12 mg/l) gave the lowest MIC values. Minimal inhibitory activity of amoxycillin (MIC90: 1.04 mg/l), cefixime (MIC90: 1.33 mg/l), cefoperazone (MIC90: 0.83 mg/l) tetracycline (MIC90: 0.29 mg/l) and minocycline (MIC90: 0.30 mg/l) was slightly lower, whereas borrelia were resistant to amikacin (MIC90: >128 mg/l). Mean minimal borreliacidal concentrations (MBCs) were representatively determined for piperacillin (MBC: 1.8 mg/l), ceftriaxone (MBC: 2.0 mg/l), azithromycin (MBC: 0.82 mg/ml), roxithromycin (MBC: 1.8 mg/l), quinupristin/dalfopristin (MBC: 5.0 mg/l), minocycline (MBC: 5.8 mg/l), and amikacin (MBC: >128 mg/l) by using conventional subculture for three weeks in combination with dark-field microscopy. B. garinii proved to be the most susceptible of the genospecies tested. Our study showed excellent in vitro antimicrobial activity of all classes of antibiotics tested, except the aminoglycosides and hence their suitability for therapy of Lyme disease. (C) 2000 Elsevier Science B.V. and International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:11 / 17
页数:7
相关论文
共 21 条
[1]  
BaradaranDilmaghani R, 1996, INFECTION, V24, P60, DOI 10.1007/BF01780660
[2]  
BOERNER J, 1995, ZBL BAKT-INT J MED M, V283, P49
[3]   In vitro activities of the everninomicin SCH 27899 and other newer antimicrobial agents against Borrelia burgdorferi [J].
Dever, LL ;
Torigian, CV ;
Barbour, AG .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (07) :1773-1775
[4]   COMPARATIVE IN-VITRO ACTIVITIES OF CLARITHROMYCIN, AZITHROMYCIN, AND ERYTHROMYCIN AGAINST BORRELIA-BURGDORFERI [J].
DEVER, LL ;
JORGENSEN, JH ;
BARBOUR, AG .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (08) :1704-1706
[5]   INVITRO ANTIMICROBIAL SUSCEPTIBILITY TESTING OF BORRELIA-BURGDORFERI - A MICRODILUTION MIC METHOD AND TIME-KILL STUDIES [J].
DEVER, LL ;
JORGENSEN, JH ;
BARBOUR, AG .
JOURNAL OF CLINICAL MICROBIOLOGY, 1992, 30 (10) :2692-2697
[6]   INVITRO ACTIVITY OF VANCOMYCIN AGAINST THE SPIROCHETE BORRELIA-BURGDORFERI [J].
DEVER, LL ;
JORGENSEN, JH ;
BARBOUR, AG .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (05) :1115-1121
[7]   In vitro susceptibility testing of Borrelia burgdorferi by a dialysis culture method [J].
Dever, LL ;
Jorgensen, JH ;
Barbour, AG .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (05) :1208-1208
[8]  
HANSEN K, 1992, ACTA DERM-VENEREOL, V72, P297
[9]   CEFOTAXIME VERSUS PENICILLIN IN THE LATE STAGE OF LYME-DISEASE - PROSPECTIVE, RANDOMIZED THERAPEUTIC STUDY [J].
HASSLER, D ;
ZOLLER, L ;
HAUDE, M ;
HUFNAGEL, HD ;
HEINRICH, F ;
SONNTAG, HG .
INFECTION, 1990, 18 (01) :16-20
[10]   New colorimetric microdilution method for in vitro susceptibility testing of Borrelia burgdorferi against antimicrobial substances [J].
Hunfeld, KP ;
Kraiczy, P ;
Wichelhaus, TA ;
Schäfer, V ;
Brade, V .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2000, 19 (01) :27-32